ACCREDITATION AND CREDIT DESIGNATION STATEMENTS
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation. The Endocrine Society designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

STATEMENT OF INDEPENDENCE
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, The Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed by the Androgens in Men Task Force with minimum input from members of the Clinical Guidelines Subcommittee, Clinical Affairs Core Committee, and Council. Task Force members had final responsibility for and control over content presented in this CME activity.

LEARNING OBJECTIVES Upon completion of this educational activity, learners will be able to:

1. Perform the appropriate evaluation of an obese man with type
2 diabetes mellitus with a low serum total testosterone level.
2. Recognize when further urological evaluation is reasonable in an older hypogonadal man receiving testosterone therapy.
3. Recognize when a dosage adjustment is desirable in a hypogonadal man treated with injectable testosterone.
4. State the most common cause of erectile dysfunction in a middle-aged man with normal sexual desire and drive.
5. Optomize dosage in a hypogonadal man receiving injectable testosterone therapy.

TARGET AUDIENCE
This continuing medical education activity should be of substantial interest to endocrinologists and other health care professionals who treat men with androgen deficiency syndromes.

DISCLOSURE POLICY
The faculty, committee members, and staff involved in planning this CME activity are required to disclose to learners any relevant financial relationship(s) that have occurred within the last 12 months with any commercial interest(s) whose products or services are discussed in the CME content. Such relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent faculty with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments. It remains for learners to determine whether financial interests or relationships may influence the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following committee members who planned and/or reviewed content for this activity reported relevant financial relationships:
*Shalender Bhasin, MD (chair) has received research grants from Abbott Laboratories, Merck, and Ligand. He has received consulting fees from GSK and Novartis. Glenn R. Cunningham, MD has received consulting fees for serving as a speaker and advisory board member Abbott Laboratories and Endo Pharmaceuticals. Alvin M. Matsumoto, MD has received research support from GSK, Abbott Laboratories, and Ascend and consulting fees from Endo Pharmaceuticals. He received royalties from serving on the editorial board for UpToDate. Peter J. Snyder, MD has received research supplies and funding from Abbott Laboratories. Ronald S. Swerdloff, MD has received consulting fees from Clarus and Endo Pharmaceuticals. He received a grant from Abbott Laboratories.

The following committee members who planned and/or reviewed content for this activity reported no relevant financial relationships:
Bradley Anawalt, MD (CME content reviewer), Frances J. Hayes, MB, FRCPI, Victor M. Montori, MD, and Patricia Stephens, PhD (medical writer) reported no relevant financial relationships.

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

COMMERCIAL SUPPORT
This activity is not supported by grants, other funds, or in-kind contributions from commercial supporters.

POLICY ON UNLABELED/OFF-LABEL USAGE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such "off-label" use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY & CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

INSTRUCTIONS FOR RECEIVING CME
This enduring activity is accessible online in Internet Explorer 7+, Firefox 2+, Safari, Opera, and Google Chrome, and on The Endocrine Society website at: http://www.endo-society.org/education/CME/index.cfm. To receive a maximum of 2 AMA PRA Category 1 Credits™ participants should (1) review the learning objectives and disclosure information (2) read and study the content, and (3) complete and submit the post test and CME evaluation as instructed.

The estimated time to complete this activity, including review of material, is 2 hours.

Last Review Date: May 2010
Activity release date: June 2010
Activity expiration date: June 2013

If you have questions about this CME activity, please direct them to education@endo-society.org.

I have read the CME guidelines outlined.